Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 81–90 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 81
- Medicine slug
- aminocaproic-acid
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5dc0c33-a0f9-43c4-9f10-3668f4361b87 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36283eb3-f98e-446f-ade7-ce7864cd5779 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a0d4fa5-8608-4e83-b5c7-d7e088d80281 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:828568a7-1808-4330-b466-01889b2311a2 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a22e559-2dac-42d7-af8d-eb0ebbc2f76d (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:555a0910-dbeb-4643-8b3a-c9fe9b803b3c (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for Aminocaproic Acid Tablets is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08bfb83e-3ac5-4e66-84a3-fcd4deaf73ae (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3cadb3a-4f63-06ee-0dd2-6828dbc1fffa (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfa601c4-b649-417e-a301-b246f080f1eb (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48c6a773-7cde-4271-876a-4570a301f43a (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afffd309-3819-07c6-e053-2995a90a948b (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:871ec401-30f8-4154-a16e-b82dc1e04b49 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ff09f58-c225-4792-9f1e-9d2b7a413521 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15eadaf4-5801-8044-e063-6394a90a72cf (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4f65667-c349-420b-b7b7-f20f3a4e4d4e (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c5bc1dd-e9ec-44c1-9281-67ad482315d9 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9205fb6b-24a0-1138-fd7b-cc33d0df5d6f (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d08ad63-71f5-4286-9622-84295668a293 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15aa2f36-ccc6-431a-99a2-45d812ef4bbf (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c2612ab-86a4-4c54-a5c0-e837f755965f (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for Aminocaproic Acid Tablets is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89aa9680-d06c-4b5b-8908-c38a08e6466a (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d6560a3-c67e-428e-b9b8-fab538856b41 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2144bf8-1a26-4958-ba10-5358bd69cd23 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b8f0ddb-00fd-4c22-afae-afe636f95f3a (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2612ee97-1723-40f2-99e6-3a736f63200f (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4629d585-134b-a479-e063-6294a90a3432 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65efb08a-c1ae-4bb7-a8a2-b7ae26485567 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for aminocaproic acid is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9f615a0-119c-4553-93a7-b30025b5fe14 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
The terminal elimination half-life for Aminocaproic Acid Oral Solution is approximately 2 hours.
Projected row 82
- Medicine slug
- aminocaproic-acid
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
1.2 ± 0.45 hours
- Numeric value
- 1.2
- Unit
- hours
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5dc0c33-a0f9-43c4-9f10-3668f4361b87 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36283eb3-f98e-446f-ade7-ce7864cd5779 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a0d4fa5-8608-4e83-b5c7-d7e088d80281 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:828568a7-1808-4330-b466-01889b2311a2 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a22e559-2dac-42d7-af8d-eb0ebbc2f76d (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:555a0910-dbeb-4643-8b3a-c9fe9b803b3c (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08bfb83e-3ac5-4e66-84a3-fcd4deaf73ae (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3cadb3a-4f63-06ee-0dd2-6828dbc1fffa (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfa601c4-b649-417e-a301-b246f080f1eb (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48c6a773-7cde-4271-876a-4570a301f43a (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afffd309-3819-07c6-e053-2995a90a948b (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:871ec401-30f8-4154-a16e-b82dc1e04b49 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ff09f58-c225-4792-9f1e-9d2b7a413521 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15eadaf4-5801-8044-e063-6394a90a72cf (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4f65667-c349-420b-b7b7-f20f3a4e4d4e (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c5bc1dd-e9ec-44c1-9281-67ad482315d9 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9205fb6b-24a0-1138-fd7b-cc33d0df5d6f (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d08ad63-71f5-4286-9622-84295668a293 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15aa2f36-ccc6-431a-99a2-45d812ef4bbf (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c2612ab-86a4-4c54-a5c0-e837f755965f (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89aa9680-d06c-4b5b-8908-c38a08e6466a (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d6560a3-c67e-428e-b9b8-fab538856b41 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2144bf8-1a26-4958-ba10-5358bd69cd23 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b8f0ddb-00fd-4c22-afae-afe636f95f3a (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2612ee97-1723-40f2-99e6-3a736f63200f (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4629d585-134b-a479-e063-6294a90a3432 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65efb08a-c1ae-4bb7-a8a2-b7ae26485567 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9f615a0-119c-4553-93a7-b30025b5fe14 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
Projected row 83
- Medicine slug
- aminocaproic-acid
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
23.1 ± 6.6 L
- Numeric value
- 23.1
- Unit
- L
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5dc0c33-a0f9-43c4-9f10-3668f4361b87 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36283eb3-f98e-446f-ade7-ce7864cd5779 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a0d4fa5-8608-4e83-b5c7-d7e088d80281 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:828568a7-1808-4330-b466-01889b2311a2 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a22e559-2dac-42d7-af8d-eb0ebbc2f76d (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:555a0910-dbeb-4643-8b3a-c9fe9b803b3c (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08bfb83e-3ac5-4e66-84a3-fcd4deaf73ae (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3cadb3a-4f63-06ee-0dd2-6828dbc1fffa (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfa601c4-b649-417e-a301-b246f080f1eb (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48c6a773-7cde-4271-876a-4570a301f43a (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afffd309-3819-07c6-e053-2995a90a948b (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:871ec401-30f8-4154-a16e-b82dc1e04b49 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ff09f58-c225-4792-9f1e-9d2b7a413521 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15eadaf4-5801-8044-e063-6394a90a72cf (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4f65667-c349-420b-b7b7-f20f3a4e4d4e (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c5bc1dd-e9ec-44c1-9281-67ad482315d9 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9205fb6b-24a0-1138-fd7b-cc33d0df5d6f (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d08ad63-71f5-4286-9622-84295668a293 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15aa2f36-ccc6-431a-99a2-45d812ef4bbf (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c2612ab-86a4-4c54-a5c0-e837f755965f (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89aa9680-d06c-4b5b-8908-c38a08e6466a (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d6560a3-c67e-428e-b9b8-fab538856b41 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2144bf8-1a26-4958-ba10-5358bd69cd23 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b8f0ddb-00fd-4c22-afae-afe636f95f3a (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2612ee97-1723-40f2-99e6-3a736f63200f (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4629d585-134b-a479-e063-6294a90a3432 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65efb08a-c1ae-4bb7-a8a2-b7ae26485567 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9f615a0-119c-4553-93a7-b30025b5fe14 (opens source in a new tab)
Aminocaproic Acid label
Version not recorded · Effective date not recorded
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD).
Projected row 84
- Medicine slug
- aminolevulinic-acid
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 3
- Source count
- 2
- Agreement rate
- 0.5
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:650daa9f-aeec-49ce-95b9-5fa20b988afd (opens source in a new tab)
Aminolevulinic Acid label
Version not recorded · Effective date not recorded
The median T max (time at which C max occurred) was 3 hours.
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cdeded66-0017-42cf-9471-13f231014323 (opens source in a new tab)
Aminolevulinic Acid label
Version not recorded · Effective date not recorded
Maximum concentrations of the PpIX metabolite (T max for PpIX) occurred with a median of 4 hours and a range of 1.2 to 7.8 hours.
Projected row 85
- Medicine slug
- aminophylline
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 8
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
3 - 15 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bca324f-6999-4c16-e053-2a91aa0aee45 (opens source in a new tab)
Aminophylline label
Version not recorded · Effective date not recorded
reported. † NR = not reported or not reported in a comparable format. ** Median Population Characteristics Age Total Body Clearance* Mean (Range) †† (mL/kg/min) Half-Life Mean (Range) †† (hr) Premature neonates postnatal age 3 - 15 days postnatal age 25 - 57 days 0.29 (0.09 - 0.49) 0.64 (0.04 - 1.2) 30 (17 - 43) 20 (9.4 - 30.6) Term infants postnatal age 1 - 2 days postnatal age 3 - 30 weeks NR †
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a663ef3-881f-48bd-2689-3713b24545c2 (opens source in a new tab)
Aminophylline label
Version not recorded · Effective date not recorded
reported. † NR = not reported or not reported in a comparable format. ** Median Population Characteristics Age Total Body Clearance* Mean (Range) †† (mL/kg/min) Half-Life Mean (Range) †† (hr) Premature neonates postnatal age 3 - 15 days postnatal age 25 - 57 days 0.29 (0.09 - 0.49) 0.64 (0.04 - 1.2) 30 (17 - 43) 20 (9.4 - 30.6) Term infants postnatal age 1 - 2 days postnatal age 3 - 30 weeks NR †
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f000254-a9f1-c8c7-e063-6394a90aa33f (opens source in a new tab)
Aminophylline label
Version not recorded · Effective date not recorded
reported. † NR = not reported or not reported in a comparable format. ** Median Population Characteristics Age Total Body Clearance* Mean (Range) †† (mL/kg/min) Half-Life Mean (Range) †† (hr) Premature neonates postnatal age 3 - 15 days postnatal age 25 - 57 days 0.29 (0.09 - 0.49) 0.64 (0.04 - 1.2) 30 (17 - 43) 20 (9.4 - 30.6) Term infants postnatal age 1 - 2 days postnatal age 3 - 30 weeks NR †
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52bbc6cd-4baf-7859-e063-6394a90ac87d (opens source in a new tab)
Aminophylline label
Version not recorded · Effective date not recorded
reported. † NR = not reported or not reported in a comparable format. ** Median Population Characteristics Age Total Body Clearance* Mean (Range) †† (mL/kg/min) Half-Life Mean (Range) †† (hr) Premature neonates postnatal age 3 - 15 days postnatal age 25 - 57 days 0.29 (0.09 - 0.49) 0.64 (0.04 - 1.2) 30 (17 - 43) 20 (9.4 - 30.6) Term infants postnatal age 1 - 2 days postnatal age 3 - 30 weeks NR †
Projected row 86
- Medicine slug
- aminophylline
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 8
- Source count
- 8
- Agreement rate
- 1
- Recorded readings
0.45 L/kg
- Numeric value
- 0.45
- Unit
- L/kg
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bca324f-6999-4c16-e053-2a91aa0aee45 (opens source in a new tab)
Aminophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 - 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75c2fc3e-28ac-c1b1-e053-2991aa0aee9f (opens source in a new tab)
Aminophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 - 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a663ef3-881f-48bd-2689-3713b24545c2 (opens source in a new tab)
Aminophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 - 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f000254-a9f1-c8c7-e063-6394a90aa33f (opens source in a new tab)
Aminophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 - 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52bbc6cd-4baf-7859-e063-6394a90ac87d (opens source in a new tab)
Aminophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 - 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:819207a2-0c37-b275-e053-2a91aa0afb36 (opens source in a new tab)
Aminophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 - 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9066bdd0-cb03-40ed-abfa-1b6fb1fff607 (opens source in a new tab)
Aminophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 - 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a9dedc4-ce04-4b22-9922-81a215ff59ed (opens source in a new tab)
Aminophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 - 0.7 L/kg) based on ideal body weight.
Projected row 87
- Medicine slug
- amiodarone
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 48
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
50%
- Numeric value
- 50
- Unit
- %
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ae393d1-7469-432a-9f21-f5ebab1207d1 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d42293e9-07fa-41b4-a08b-2e388f5b1e13 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5520f11d-968d-4f4f-bf57-d14369c0d746 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:352ed423-fc16-47bb-8e25-98e1c20f9991 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8bf4aa2-abea-403d-a6d9-395caf5f87f0 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of Amiodarone Hydrochloride Tablets is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a20d0c03-cfda-49d1-88c9-be1bf295bc6c (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d912a75a-ddac-4e7b-b5c4-321d4252ec05 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4532f12-3b7a-42ab-9a6c-36fd2a3f192c (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of Amiodarone Hydrochloride Tablets is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57f7f2ea-4ca9-4ada-e063-6294a90a492b (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d911b4cf-eec4-43f8-aa64-cc60cfc901b9 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of Amiodarone Hydrochloride Tablets is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bdc2236-3a1a-4210-a9fb-38f860227aa7 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0caedb97-56fd-4ec0-bfb2-c7683b8f5f1b (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:337c5695-e3f8-41c6-a088-a492d5c60215 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of Amiodarone Hydrochloride Tablets is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02f4a736-63ed-4ad4-a1f1-b21a71e928bd (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8377eb89-0d62-48c5-90e7-e96d545a4642 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c536e0ad-2758-4022-8242-f5e9b6aca1e2 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95cef33b-c0e6-b17c-7cbb-f5c066872705 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride tablets is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfd14110-4bf8-4fbe-a888-7b23fea6ffaa (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcadce9c-d0a0-4235-8ff8-dd93c09e03b3 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f49d011f-5ca6-4f75-ba16-2099fe42f5aa (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride tablet is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c149392-a4f0-4e2d-a13f-2b94810005de (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:924c9359-ebc4-62a7-e053-2a95a90a4327 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride tablets is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51a88e8e-da02-4b97-9e7e-442fbffd908d (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28cd0224-3569-4308-bd40-480bc4230503 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of Amiodarone Hydrochloride Tablets is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3e631c5-1204-419c-8dbe-fa9b37a77f97 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ccd3733-c3af-4a11-8500-0f99194c1472 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride is approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b41cbcb5-9c5d-4e45-a4f2-952df5f22c00 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
The bioavailability of amiodarone hydrochloride tablet is approximately 50%.
Projected row 88
- Medicine slug
- amiodarone
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 48
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
58 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ae393d1-7469-432a-9f21-f5ebab1207d1 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d42293e9-07fa-41b4-a08b-2e388f5b1e13 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5520f11d-968d-4f4f-bf57-d14369c0d746 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone exhibited multi- compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:352ed423-fc16-47bb-8e25-98e1c20f9991 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8bf4aa2-abea-403d-a6d9-395caf5f87f0 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, Amiodarone Hydrochloride Tablets exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a20d0c03-cfda-49d1-88c9-be1bf295bc6c (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d912a75a-ddac-4e7b-b5c4-321d4252ec05 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4532f12-3b7a-42ab-9a6c-36fd2a3f192c (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, Amiodarone Hydrochloride Tablets exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57f7f2ea-4ca9-4ada-e063-6294a90a492b (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d911b4cf-eec4-43f8-aa64-cc60cfc901b9 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, Amiodarone Hydrochloride Tablets exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bdc2236-3a1a-4210-a9fb-38f860227aa7 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0caedb97-56fd-4ec0-bfb2-c7683b8f5f1b (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:337c5695-e3f8-41c6-a088-a492d5c60215 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, Amiodarone Hydrochloride Tablets exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02f4a736-63ed-4ad4-a1f1-b21a71e928bd (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8377eb89-0d62-48c5-90e7-e96d545a4642 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c536e0ad-2758-4022-8242-f5e9b6aca1e2 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95cef33b-c0e6-b17c-7cbb-f5c066872705 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride tablets exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfd14110-4bf8-4fbe-a888-7b23fea6ffaa (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcadce9c-d0a0-4235-8ff8-dd93c09e03b3 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f49d011f-5ca6-4f75-ba16-2099fe42f5aa (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride tablets exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c149392-a4f0-4e2d-a13f-2b94810005de (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:924c9359-ebc4-62a7-e053-2a95a90a4327 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride tablets exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51a88e8e-da02-4b97-9e7e-442fbffd908d (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28cd0224-3569-4308-bd40-480bc4230503 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, Amiodarone Hydrochloride Tablets exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3e631c5-1204-419c-8dbe-fa9b37a77f97 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ccd3733-c3af-4a11-8500-0f99194c1472 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b41cbcb5-9c5d-4e45-a4f2-952df5f22c00 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Elimination Following single dose administration in 12 healthy subjects, amiodarone hydrochloride tablets exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 days) for amiodarone and 36 days (range 14 to 75 days) for the active metabolite (DEA).
Projected row 89
- Medicine slug
- amiodarone
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 48
- Source count
- 20
- Agreement rate
- 1
- Recorded readings
>96%
- Numeric value
- 96
- Unit
- %
- Source records
- 20
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 20 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9108958-b8d7-4fba-87c3-9a32990de551 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution: From in vitro studies, the protein binding of amiodarone is >96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:66700f8b-3f76-3749-e053-2a91aa0adfdb (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination: From in vitro studies, the protein binding of amiodarone is >96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8d04647-8e25-4127-8ecf-360ce1991c2f (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination: From in vitro studies, the protein binding of amiodarone is >96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c9ee15a-5741-4aaa-8d80-c7bd2e45822e (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination: From in vitro studies, the protein binding of amiodarone is >96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d088060-70b5-e796-e053-2995a90a0969 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination From in vitro studies, the protein binding of amiodarone is > 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51772745-9ea9-42cd-97e6-7266f41ae3ca (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination: From in vitro studies, the protein binding of amiodarone is >96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a53668c-adda-44c2-a743-e79e467437e3 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination: From in vitro studies, the protein binding of amiodarone is > 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6cd870d7-6381-421a-89bc-bce5c9518219 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination: From in vitro studies, the protein binding of amiodarone is >96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8969aad3-0219-e67f-e053-2995a90aac5a (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination From in vitro studies, the protein binding of amiodarone is > 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d889c00c-e27e-4e27-e053-2995a90ad4e1 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination: From in vitro studies, the protein binding of amiodarone is >96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9772ab48-2ef1-4b9f-9a27-794f3e7e5c7a (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination: From in vitro studies, the protein binding of amiodarone is >96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81a15062-ba1e-37c0-e053-2991aa0af945 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination: From in vitro studies, the protein binding of amiodarone is >96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f00c333-9667-4ebc-8849-009a3779c0c9 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination: From in vitro studies, the protein binding of amiodarone is >96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7639dfe4-933c-2916-e053-2a91aa0a3fe7 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination: From in vitro studies, the protein binding of amiodarone is >96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:364ab45e-b525-f310-e063-6394a90a4421 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination From in vitro studies, the protein binding of amiodarone is > 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0b3b743-9f62-4b02-ace5-c8d93637ecad (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination From in vitro studies, the protein binding of amiodarone is > 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4240b2e9-be05-3de5-e063-6394a90a4bb2 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination: From in vitro studies, the protein binding of amiodarone is > 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9151c1b-b70c-477b-868a-fffdc5c51830 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination: From in vitro studies, the protein binding of amiodarone is >96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a28ae25-7cc4-4ac0-a2ba-7820fb93e25c (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination From in vitro studies, the protein binding of amiodarone is > 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcc8658c-761a-443f-8c32-1499d86028ec (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Distribution/Elimination From in vitro studies, the protein binding of amiodarone is > 96%.
Projected row 90
- Medicine slug
- amiodarone
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 48
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
60 L/kg
- Numeric value
- 60
- Unit
- L/kg
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ae393d1-7469-432a-9f21-f5ebab1207d1 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d42293e9-07fa-41b4-a08b-2e388f5b1e13 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5520f11d-968d-4f4f-bf57-d14369c0d746 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone Hydrochloride Tablets has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:352ed423-fc16-47bb-8e25-98e1c20f9991 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8bf4aa2-abea-403d-a6d9-395caf5f87f0 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone Hydrochloride Tablets has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a20d0c03-cfda-49d1-88c9-be1bf295bc6c (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d912a75a-ddac-4e7b-b5c4-321d4252ec05 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4532f12-3b7a-42ab-9a6c-36fd2a3f192c (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone Hydrochloride Tablets has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57f7f2ea-4ca9-4ada-e063-6294a90a492b (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d911b4cf-eec4-43f8-aa64-cc60cfc901b9 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone Hydrochloride Tablets has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bdc2236-3a1a-4210-a9fb-38f860227aa7 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0caedb97-56fd-4ec0-bfb2-c7683b8f5f1b (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:337c5695-e3f8-41c6-a088-a492d5c60215 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone Hydrochloride Tablets has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02f4a736-63ed-4ad4-a1f1-b21a71e928bd (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Pacerone has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Pacerone has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8377eb89-0d62-48c5-90e7-e96d545a4642 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c536e0ad-2758-4022-8242-f5e9b6aca1e2 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95cef33b-c0e6-b17c-7cbb-f5c066872705 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride tablets have a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfd14110-4bf8-4fbe-a888-7b23fea6ffaa (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcadce9c-d0a0-4235-8ff8-dd93c09e03b3 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Pacerone has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f49d011f-5ca6-4f75-ba16-2099fe42f5aa (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride tablets has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c149392-a4f0-4e2d-a13f-2b94810005de (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:924c9359-ebc4-62a7-e053-2a95a90a4327 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride tablets have a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51a88e8e-da02-4b97-9e7e-442fbffd908d (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28cd0224-3569-4308-bd40-480bc4230503 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone Hydrochloride Tablets has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3e631c5-1204-419c-8dbe-fa9b37a77f97 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ccd3733-c3af-4a11-8500-0f99194c1472 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b41cbcb5-9c5d-4e45-a4f2-952df5f22c00 (opens source in a new tab)
Amiodarone label
Version not recorded · Effective date not recorded
Amiodarone hydrochloride tablets has a very large but variable volume of distribution, averaging about 60 L/kg, because of extensive accumulation in various sites, especially adipose tissue and highly perfused organs, such as the liver, lung, and spleen.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=80Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.